First Multicentre Clinical Results of Human Umbilical Cord Blood Platelet-Rich Plasma for Endometrial Restoration
A newly published first-in-human, multicentre pilot study evaluates hysteroscopic subendometrial human umbilical cord blood platelet-rich plasma (hUC-PRP) injections in women with refractory Asherman’s syndrome, endometrial atrophy, or thin endometrium. According to Reproductive BioMedicine Online, the research offers a novel regenerative approach for female patients facing infertility-related endometrial disorders who currently suffer from a lack of gold-standard treatments.
Clinical Outcomes and Vascular Changes After Treatment
Led by Paula Alonso-Frías, a PhD candidate at the IVI Foundation, the research team demonstrated that hUC-PRP administration is associated with measurable improvements in endometrial thickness, endometrial pattern, and neoangiogenesis. The study integrates extensive proteomic and metabolomic characterisation of hUC-PRP with clinical, vascular, and transcriptomic endometrial analyses. These investigations reveal transcriptomic changes consistent with enhanced proliferation, angiogenesis, hormone responsiveness, and extracellular matrix remodeling, suggesting the activation of a reparative endometrial environment.
Research Team and Collaborating Institutions
The published findings are the result of collaborative work. Alongside Paula Alonso-Frías, the author team includes Adolfo Rodríguez-Eguren, Clara Bueno-Fernandez, María Gómez-Álvarez, Marcos Agustina-Hernández, Emilio Francés-Herrero, Mónica Romeu, Carmen Vidal, Lucía de Miguel-Gómez, Amparo Faus, Ana Monzó, Amparo Carrasco, Antonio Parraga-Leo, Patricia Díaz-Gimeno, Leonor Senent, Carmen Lloret-Sos, María Dolores Gómez-Ruiz, Pedro Asensi Cantó, Pilar Solves, Inés Gómez-Seguí, Begoña Laiz-Marro, Antonio Pellicer, and Irene Cervelló. Alonso-Frías specifically thanked Irene Cervelló Alcaraz for guidance and support, alongside the IVI Foundation for backing the research.
What conditions did the pilot study target?
What specific conditions did the pilot study target?
The clinical trial evaluated patients suffering from refractory Asherman’s syndrome, endometrial atrophy, and thin endometrium. These conditions are characterized by infertility-related endometrial disorders that currently lack established gold-standard treatments.
How was the platelet-rich plasma administered during the study?
Researchers used hysteroscopic subendometrial injections to deliver human umbilical cord blood platelet-rich plasma directly into the targeted tissue. This delivery method was paired with extensive proteomic and metabolomic characterization of the plasma itself.
Where was the complete clinical study published?
The findings were published open access in Reproductive BioMedicine Online and are available to read in full within the journal’s in-press articles section.
Worth a look